We are live on ! Find out more
NYMX

Nymox Pharmaceutical Corp

Delisted

NYMX was delisted on the 6th of July, 2023.

59 hedge funds and large institutions have $13.3M invested in Nymox Pharmaceutical Corp in 2021 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 21 increasing their positions, 13 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

246% more call options, than puts

Call options by funds: $45K | Put options by funds: $13K

62% more repeat investments, than reductions

Existing positions increased: 21 | Existing positions reduced: 13

33% more first-time investments, than exits

New positions opened: 4 | Existing positions closed: 3

2% more funds holding

Funds holding: 5859 (+1)

6% less capital invested

Capital invested by funds: $14.2M → $13.3M (-$924K)

Holders
59
Holders Change
+1
Holders Change %
+1.72%
% of All Funds
1.04%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
4
Increased
21
Reduced
13
Closed
3
Calls
$45K
Puts
$13K
Net Calls
+$32K
Net Calls Change
+$89K
Name Holding Trade Value Shares
Change
Change in
Stake
Citigroup
51
Citigroup
New York
$7K -$11.8K -4,490 -59%
Osaic Holdings
52
Osaic Holdings
Arizona
$6K -$4.22K -1,600 -38%
SIAP
53
Sterling Investment Advisors (Pennsylvania)
Pennsylvania
$6K
Bank of Montreal
54
Bank of Montreal
Ontario, Canada
$5K -$13.9K -5,264 -73%
Rockefeller Capital Management
55
Rockefeller Capital Management
New York
$4K
Group One Trading
56
Group One Trading
Illinois
$2K +$2.66K +1,010 +4,810%
AIG
57
American International Group
New York
$55 +$171 +65 +0.3%
Renaissance Technologies
58
Renaissance Technologies
New York
-$168K -67,564 Closed
Russell Investments Group
59
Russell Investments Group
United Kingdom
-$54K -21,941 Closed
Squarepoint
60
Squarepoint
New York
-$29K -11,816 Closed
Fidelity Investments
61
Fidelity Investments
Massachusetts
+$511 +194 New

NYMX Hedge Fund Activity: Q1 2021 in Review

59 of the 5,696 institutional investors tracked by Wall St. Rank reported a position in Nymox Pharmaceutical Corp (NYMX) for Q1 2021, worth a combined $13.3M — down 6.5% from $14.2M a quarter earlier.

Buyers outnumbered sellers: 4 funds opened new NYMX positions and 3 closed out — a net gain of 1 holder — while 21 added to existing stakes and 13 trimmed.

The largest buyer was Wells Fargo, adding an estimated $505K. The largest seller was Renaissance Technologies, exiting entirely with an estimated $168K sold.

  • 59 institutional investors held Nymox Pharmaceutical Corp (NYMX) as of Q1 2021, up from 58 in Q4 2020.
  • Funds reported $13.3M of Nymox Pharmaceutical Corp stock for Q1 2021, down 6.5% quarter-over-quarter.
  • 4 funds opened new Nymox Pharmaceutical Corp positions in Q1 2021 and 3 closed out, a net change of +1 holder.
  • The largest Nymox Pharmaceutical Corp buyer in Q1 2021 was Wells Fargo, an estimated $505K added.
  • The largest Nymox Pharmaceutical Corp seller in Q1 2021 was Renaissance Technologies, an estimated $168K sold.

Based on aggregated 13F filings for Q1 2021.